*Pulmonary Disease, Chronic Obstructive/diagnosis/drug therapy/epidemiology

Whittaker, H. R., Torkpour, A., & Quint, J. (2024). Eligibility of patients with chronic obstructive pulmonary disease for inclusion in randomised control trials investigating triple therapy: a study using routinely collected data. Respir Res, 25, 43. http://doi.org/10.1186/s12931-024-02672-x
Requena, G., Czira, A., Banks, V., Wood, R., Tritton, T., Castillo, C., et al. (2023). Comparative Effectiveness of Umeclidinium/Vilanterol versus Indacaterol/Glycopyrronium on Moderate-to-Severe Exacerbations in Patients with Chronic Obstructive Pulmonary Disease in Clinical Practice in England. Int J Chron Obstruct Pulmon Dis, 18, 2039-2054. http://doi.org/10.2147/copd.s408688
Suissa, S., Dell'Aniello, S., & Ernst, P. (2022). Single-Inhaler Triple versus Dual Bronchodilator Therapy in COPD: Real-World Comparative Effectiveness and Safety. Int J Chron Obstruct Pulmon Dis, 17, 1975-1986. http://doi.org/10.2147/copd.s378486
Rebordosa, C., Plana, E., Rubino, A., Aguado, J., Martinez, D., Lei, A., et al. (2022). Risk Assessment of Acute Myocardial Infarction and Stroke Associated with Long-Acting Muscarinic Antagonists, Alone or in Combination, versus Long-Acting beta2-Agonists. Int J Chron Obstruct Pulmon Dis, 17, 1715-1733. http://doi.org/10.2147/copd.s363997
Sansbury, L. B., Lipson, D. A., Bains, C., Anley, G. A., Rothnie, K. J., & Ismaila, A. S. (2022). Disease Burden and Healthcare Utilization Among Patients with Chronic Obstructive Pulmonary Disease (COPD) in England. Int J Chron Obstruct Pulmon Dis, 17, 415-426. http://doi.org/10.2147/copd.s336158
Sansbury, L. B., Rothnie, K. J., Bains, C., Compton, C., Anley, G., & Ismaila, A. S. (2021). Healthcare, Medication Utilization and Outcomes of Patients with COPD by GOLD Classification in England. Int J Chron Obstruct Pulmon Dis, 16, 2591-2604. http://doi.org/10.2147/copd.s318969